Efficacy and Safety of Fremanezumab for Episodic Cluster Headache

Study Title
A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)
Teva Identifier
TV48125-CNS-30056 | 2016-003278-42
ClinicalTrials.gov Identifier
NCT02945046
Study Status
Terminated
Trial Condition(s)
Episodic Cluster Headache
Interventions
Drug: Fremanezumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 70 Years
Trial Duration
January 19, 2017 - May 13, 2019
Phase
Phase 3

Additional info

Study Type

Interventional